Lucigen | GenomeWeb

Lucigen

The exclusive agreement covers a portfolio of Epicentre products for transposomics, microarray analysis, and transcriptomics research.

The CSPro certification program is a two-step process that includes minimum data generation, data certification, and an on-site audit of a facility and its processes.

The firm presented results of a pre-clinical evaluation of the test and platform yesterday at the Next Generation Dx Summit in Washington, DC. 

Lucigen's CEO said the agreement will provide researchers in India with his firm's technologies for use with NGS, cloning, and protein expression systems.

The proceeds will be used to fund development of a molecular diagnostics platform and for clinical trials to gain FDA approval for the platform.

NEW YORK (GenomeWeb) – Using fever to screen for Ebola casts a wide net, while standard RT-PCR requires many hours and expert technicians.

A majority of these assays use standard RT-PCR, but a few have novel methodologies that may help control the current outbreak in Africa, prevent an outbreak in the US, and possibly advance the field of molecular diagnostics.

NEW YORK (GenomeWeb) – Lucigen announced yesterday that it has partnered with Thermo Fisher Scientific to develop and launch a long mate pair library kit for the Ion Torrent Personal Genome Machine sequencing platform.

Lucigen has hired David Theil as senior vice president and CFO.

NEW YORK (GenomeWeb) — Lucigen has entered phase two of a five-year, $1.7 million, Small Business Innovation Research grant from the National Institute of Allergy and Infectious Diseases to develop a nucleic acid test for three types of viral hemorrhagic fever: Ebola, Lassa, and Marburg.

Pages

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.